Atai Life Sciences N.V. ATAI

$4.48 -0.80 (-15.15%)

Valuation

Market cap
1,250,718,000
Revenue TTM
$310,000
Net income TTM
$-149,270,000
PE ratio
0.00
Forward PE
—
Profit margin
-48,151.61%
Debt to equity
0.00

Trading

Volume
10,284,041
Avg volume
5,985,524
Day's range
$4.45 – $5.22
Shares out
233,779,000
Stochastic %K
10%
Beta
1.59
Analysts
Strong Sell
Price target
$12.12

Price

Company profile

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options. Its pipeline includes BPL-003 (mebufotenin benzoate), an intranasal formulation in Phase 2 and 3 clinical studies for treatment-resistant depression and alcohol use d...

Show more

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options. Its pipeline includes BPL-003 (mebufotenin benzoate), an intranasal formulation in Phase 2 and 3 clinical studies for treatment-resistant depression and alcohol use disorder; ELE-101, a serotonergic psychedelic for major depressive disorder; and RL-007, an orally bioavailable pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia. The company's pipeline also comprises VLS-01, an oral transmucosal film formulation of N, N-Dimethyltryptamine in Phase 2 clinical study for treatment-resistant depression; EMP-01, an oral formulation of the R-enantiomer of 3,4-methylenedioxy-methamphetamine in Phase 2 clinical study for social anxiety disorder; and EGX-A and EGX-B, non-hallucinogenic 5-HT2A receptor agonists for treatment-resistant depression. Additionally, it offers COMP360, a psilocybin therapy; and GRX-917, a treatment for anxiety, depression, and various neurological disorders. The company has additional operations in Germany and Canada. AtaiBeckley Inc. was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. AtaiBeckley Inc. operates as a subsidiary of Eli Lilly and Company.

Industry
Biotechnology
Sector
Healthcare
Phone
332 282 0507
Website
https://www.ataibeckley.com
Address
250 West 34th Street, New York, United States

Latest news

Stocktwits

OmFm Oct 12, 3:23 PM
$ATAI why? you want to throw money away?
0 replies
directorwalsh Oct 2, 7:57 PM
$GHRS started position here. Still a ways to go but elite data + interesting pipeline. ~$1B EV with ample cash is too low here. Better version of $ATAI compound Lilly is paying $3B+ for.
0 replies
leLu83 Oct 2, 2:52 PM
$GHRS only acquisition target left $ATAI
0 replies
TheRealShortSqueezy Sep 30, 1:32 PM
$OPTH THE PATH TO A MUCH BIGGER MARKET Optimi Health is making a major move from psychedelic manufacturing into its own clinical development programs. 🧬 Phase 2 Psilocybin: up to 200 patients with Major Depressive Disorder 🧬 Phase 3 MDMA: up to 100 patients with PTSD 🧬 300 patients combined across two Health Canada authorized trials 🧬 Latest 5mg psilocybin batch manufactured for both clinical + commercial use 🧬 Already commercially supplying regulated markets including Australia How could OPTH monetize this? 💰 Optimi manufactures its own drugs + owns its clinical data, creating potential for registrations, licensing and global commercial sales. With programs targeting Major Depressive Disorder + PTSD, OPTH is pursuing multibillion dollar treatment markets 💰 Analyst Coverage: On May 27, 2026, Diamond Equity Research initiated coverage with an illustrative DCF valuation of $15.00 per share Communicated Disclaimer: https://stockresearchtoday.com/opth/ Sector Peers: $CMPS $ATAI $IXHL
0 replies
TheRealShortSqueezy Sep 29, 6:37 PM
$OPTH ADDS MORE EXPERIENCE TO THE BOARD Optimi Health appointed Melanie Pump to its Board of Directors, bringing 25+ years of senior finance and leadership experience. ▫️ 25+ years in finance and corporate leadership ▫️ 20+ years working with public companies ▫️ Currently CFO of Qu Data Centres ▫️ Experience across technology, fintech and high growth companies ▫️ OPTH is advancing a Phase 2 psilocybin trial for up to 200 patients and a Phase 3 MDMA trial for up to 100 patients More financial and governance experience being added as OPTH continues building out its clinical and commercial strategy. Sector Peers: $CMPS $ATAI $GHRS
1 replies
TheRealShortSqueezy Sep 28, 5:48 PM
$OPTH IS A BULLISH WEDGE BUILDING ? 📈 Optimi Health continues to tighten inside a bullish wedge, with price compressing toward the apex. 🔹 $5.58 first key level to reclaim 🔹 $6.18 ➡️ $6.57 next resistance zone 🔹 $8.42 becomes the major level above 🔹 Breakout with volume could confirm the move OPTH has a Health Canada authorized Phase 2 psilocybin trial for up to 200 patients and Phase 3 MDMA trial for up to 100 patients. Even more interesting, Optimi is already commercially supplying psilocybin and MDMA while advancing both clinical programs. Communicated Disclaimer: https://stockresearchtoday.com/opth/ Sector Peers: $CMPS $ATAI $GHRS $DFTX
1 replies
TheRealShortSqueezy Sep 28, 1:32 PM
$OPTH ONE PSYCHEDELIC NAME WORTH WATCHING Optimi Health is a Canadian pharmaceutical company producing GMP grade psilocybin and MDMA for regulated mental health treatments and clinical trials. Recent milestones are stacking up: 🔹 200 patients targeted in its Health Canada authorized Phase 2 psilocybin trial for Major Depressive Disorder 🔹 100 patients planned for its Phase 3 MDMA trial targeting PTSD in veterans and frontline workers 🔹 Latest batch of 5mg psilocybin capsules completed and quality released for clinical + commercial use 🔹 Commercial psychedelic supply already reaching regulated markets including Canada + Australia With 100M+ people estimated to suffer from treatment resistant depression and 300M+ from PTSD globally, the addressable patient population is significant. The global psychedelic drugs market is estimated at $2.04B in 2026 and projected to reach $5.16B by 2034 💰 Communicated Disclaimer: https://stockresearchtoday.com/opth/ Sector Peers : $CMPS $ATAI $GHRS
0 replies
CoffeeRocks Sep 25, 1:34 AM
$CATX $ATAI $VKTX $IOVA 0pportunity with recent selloff
0 replies